An Interview With PharmAsia News: Pharmatech's Bikash Chatterjee And Chat Kwan On China's New GMP Guidelines
This article was originally published in The Pink Sheet Daily
Executive Summary
China's shift to a global standard means companies must invest in a more reproducible supply chain, which translates to a more predictable manufacturing and distribution operation.
You may also be interested in...
USP Tightens Supply Chain Controls with Risk-Based Vendor Qualification; Aims To Prevent New Heparin Crisis
The U.S. Pharmacopeia is taking a forward-looking, risk-based approach to protecting the supply chain for biological drug products from intentional and unintentional adulteration, even as it adds testing requirements aimed at preventing a new heparin crisis
China Releases Strictest Ever GMP Draft Guidelines; Laxer Standards Urged For Local Companies
SHANGHAI - China's State FDA recently published a new draft version of Good Manufacturing Practice guidelines for pharmaceuticals on its website for public comment
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.